Free iron, total F-isoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin.
about
Neurotoxins: free radical mechanisms and melatonin protectionTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesNeuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemiaPathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal modelsRedox imbalance and morphological changes in skin fibroblasts in typical Rett syndromeOxidative brain damage in Mecp2-mutant murine models of Rett syndromeNitrosothiol formation and protection against Fenton chemistry by nitric oxide-induced dinitrosyliron complex formation from anoxia-initiated cellular chelatable iron increasePartial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oilDocosahexaenoic acid augments hypothermic neuroprotection in a neonatal rat asphyxia modelIsoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus.Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder.Melatonin in the management of perinatal hypoxic-ischemic encephalopathy: light at the end of the tunnel?Role of Antioxidants in Neonatal Hypoxic-Ischemic Brain Injury: New Therapeutic Approaches.Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury.Pathophysiological role of inflammatory molecules in paediatric ischaemic brain injury.New pharmacologic and therapeutic approaches for hypoxic-ischemic encephalopathy in the newborn.Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review.Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury.Unresolved issues in the analysis of F2-isoprostanes, F4-neuroprostanes, isofurans, neurofurans, and F2-dihomo-isoprostanes in body fluids and tissue using gas chromatography/negative-ion chemical-ionization mass spectrometry.Protection of melatonin in experimental models of newborn hypoxic-ischemic brain injury through MT1 receptor.Assessment of oxidative stress biomarkers - neuroprostanes and dihomo-isoprostanes - in the urine of elite triathletes after two weeks of moderate-altitude training.MtDNA mutagenesis impairs elimination of mitochondria during erythroid maturation leading to enhanced erythrocyte destruction.Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.Melatonin alleviates lipopolysaccharide-induced placental cellular stress response in mice.Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates.Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema.
P2860
Q22305781-8AAE2F7B-182D-4F18-ACC2-1CA30D439FD2Q24289511-7AFF580B-2CED-4541-8C55-ACE0EE46A34AQ26999039-867516A7-15E5-458F-A6CC-91A28CE7735CQ27000069-E320C065-F186-46E1-9342-3EEB63973818Q33765360-59545864-B697-44D6-9E05-51B598F9AB7CQ33826769-219425FC-DE62-4153-A50C-DA2327968A95Q33931109-0C01BCFF-0572-41D8-9226-7FB19F51CB3EQ36049510-9675DB1B-2E3A-4AB3-A397-E2A465040B9AQ36486153-9D0D8E3B-D2D8-4B22-B25D-AE87C9ABCD02Q36650599-0ED42684-4BA4-4CED-AC3C-D5CE8D416D1BQ36970130-F6B80A3B-A5B1-4893-A94F-07A823D161CBQ37302940-DF95B4EE-1232-4CCE-B2D0-63ABFED1ACB4Q37690680-ECC8E904-9708-4443-BF59-69568E2F2C95Q37905540-AEB86FC6-CC1E-4ADD-9188-A920BA1CC7D0Q37976090-A78A973C-AA41-4738-A808-CECC2E876548Q37981711-4DBED546-2F53-4E21-A87A-4C14CA7C1E7DQ38191261-5F631038-9856-43FE-B2A6-E634FE3F98A0Q38248001-ECCA8B76-D7CD-451B-80F2-C9DF02028BD6Q38392133-EDA3F283-85DF-4710-8DA0-5A3088890EDDQ38630639-8E2DE107-C38A-49E4-B53B-870E2CDE8CF0Q40390995-28ED1A87-5A3F-468A-A6A5-C461AF1C1D05Q41268799-9D106ABF-3473-466D-8880-4539CA2C38E2Q41931096-72CA2631-B1B3-4773-8E48-7C10AF4FCF40Q42748318-A5C07BCE-F538-410E-BD02-37C6A43BED0FQ47940557-4BFAAB0B-3FB9-43EA-B6B1-EAF0974B29BDQ55361401-E6585B2C-6AB1-482F-AE51-0F31C64108A8
P2860
Free iron, total F-isoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@en
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@nl
type
label
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@en
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@nl
prefLabel
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@en
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@nl
P2093
P2860
P50
P1476
Free iron, total F-isoprostane ...... rotective effect of melatonin.
@en
P2093
Cinzia Signorini
Giuseppe Buonocore
Mario Comporti
Silvia Carloni
P2860
P304
P356
10.1111/J.1600-079X.2008.00639.X
P577
2008-12-24T00:00:00Z